Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products

References

1. 1.↵
   Monoclonal antibodies for human use. Pharmeuropa 2010, 22 (I), 49–53.

   OpenUrl
2. 2.↵
   European Directorate for the Quality of Medicine. 2.9.20 Particulate Contamination: Visible Particles. In Pharmacopoea Europaea, 6th ed.; 2008, pp 381–382.
3. 3.↵
   United States Pharmacopeia. <1787>. Measurement of Subvisible Particulate Matter in Therapeutic Protein Injections. In The United States Pharmacopeia–National Formulary; USP 39 NF 6, 2013.
4. 4.↵
   United States Pharmacopeia. <790> Visible Particulates in Injections. In The United States Pharmacopeia–National Formulary; USP 37 NF 32, 2014.
5. 5.↵
   Japanese Pharmacopeia. Insoluble Particulate Matter Test for Injections. In Japanese Pharmacopeia; The Ministry of Health, Labor and Welfare Ministerial Notification No. 285, 15, 6.07, 2007.
6. 6.↵
   United States Pharmacopeia. <788> Particulate Matter in Injections, <789> Particulate Matter in Ophthalmic Solutions, and <1788> Methods for the Determination of Particulate Matter in Injections and Ophthalmic Solutions. In The United States Pharmacopeia–National Formulary; USP 34 NF 29, 2011.
7. 7.↵
   1. Bukofzer S.,
   2. Ayres J.,
   3. Chavez A.,
   4. Devera M.,
   5. Miller J.,
   6. Ross D.,
   7. Shabushnig J.,
   8. Vargo S.,
   9. Watson H.,
   10. Watson R.

   Industry perspective on the medical risk of visible particles in injectable drug products. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 123–139.

   OpenUrlFREE Full Text
8. 8.↵
   1. Staven V.,
   2. Waaseth M.,
   3. Wang S.,
   4. Gronlie I.,
   5. Tho I.

   Utilization of the Tyndall effect for enhanced visual detection of particles in compatibility testing of intravenous fluids: validity and reliability. PDA J. Pharm. Sci. Technol. 2015, 69 (2), 270–283.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Knapp J. Z.

   The scientific basis for visible particle inspection. PDA J. Pharm. Sci. Technol. 1999, 53 (6), 291–302.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Ripple D. C.,
    2. Dimitrova M. N.

    Protein particles: what we know and what we do not know. J. Pharm. Sci. 2012, 101 (10), 3568–3579.

    OpenUrlPubMed
11. 11.↵
    PubChem Open Chemistry Database. Barium Sulfate; National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health; http://pubchem.ncbi.nlm.nih.gov/compound/barium_sulfate#section=Top
12. 12.↵
    1. Kucher M.,
    2. Babic D.,
    3. Kind M.

    Precipitation of barium sulfate: experimental investigation about the influence of supersaturation and free lattice ion ratio on particle formation. Chem. Eng. Process. 2006, 45 (10), 900–907.

    OpenUrl
13. 13.↵
    1. Melchore J. A.,
    2. Berdovich D.

    Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection. PDA J. Pharm. Sci. Technol. 2012, 66 (3), 273–284.

    OpenUrlAbstract/FREE Full Text